ClinicalTrials.gg
CompletedNCT06832540Updated Nov 17, 2025

Mass Balance Study of [14C] TJ0113 in Healthy Chinese Subjects

A Phase 1 interventional study of [14C]TJ0113 in Healthy Chinese Subjects, sponsored by Hangzhou PhecdaMed Co., Ltd.. Completed at 1 site in China. Open to male participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-11-17.

Sponsored by Hangzhou PhecdaMed Co., Ltd. · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
6
Allocation
Not applicable
Ages
18 Years to 45 Years
Sex
Male
01

Study summary

Mass Balance Study of [14C] TJ0113 in Healthy Chinese Subjects

Read the detailed description

This is a single-center, single-dose and open-label trial designed to enroll 6-8 healthy adult male subjects to evaluate the mass balance of [14C]TJ0113 in these subjects. Each subject will receive a single oral dose of approximately 200 mg /100 μCi [14C]TJ0113 oral formulation; after administration, blood, urine, and stool samples will be collected at specified time points/intervals during the study. The total radioactivity in whole blood and plasma, as well as the plasma concentrations of TJ0113 and its metabolites will be determined to calculate the pharmacokinetic (PK) parameters of [14C]TJ0113 and its metabolites in plasma and whole blood as well as the PK parameters of TJ0113 and its metabolites in plasma, and to understand the distribution of total radioactivity in whole blood and plasma; the radioactivity in urine and feces will be determined to obtain the data on total recovery, excretion and main routes of excretion; the metabolic pathways of TJ0113 in humans will be determined through radiolabeled metabolite profiling and structural identification of major metabolites in plasma, urine, and feces.

02

Conditions studied

  • Healthy Chinese Subjects
03

In context

Lead sponsor

Hangzhou PhecdaMed Co., Ltd. is the lead sponsor of 5 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy Chinese males;
  2. Age at : 18-45 years (inclusive);
  3. (BMI) ranging from 19 to 26 kg/m2 (inclusive) and body weight ≥ 50 kg;
  4. Fully understand the objectives and requirements of this study, and voluntarily sign the informed consent form;
  5. Able to communicate well with study personnel and complete the study according to the protocol.

Exclusion criteria

Exclusion Criteria:

Auxiliary examination:

  1. Subjects who have abnormal and results of comprehensive physical examination, digital anal examination, laboratory tests (hematology, blood chemistry, coagulation function, urinalysis, stool routine + occult blood, thyroid function), 12-lead , ophthalmic examination (slit-lamp, intraocular pressure and fundus radiography), chest X-ray (anteroposterior) and abdominal B ultrasound (liver, gallbladder, pancreas, spleen and kidney);
  2. Subjects with unqualified vital signs that remain unqualified upon retesting;
  3. Subjects who have a resting interval (QTcF) > 450 ms (corrected according to Fridericia's formula) or QRS > 120 ms as determined by 12-lead electrocardiogram (ECG), or a previous history of long QT syndrome;
  4. Subjects who have any clinically significant abnormality in surface antigen, hepatitis B E antigen, virus antibody (anti-HCV), treponema pallidum antibody test, and antibody (anti-HIV) as judged by the investigator;

    Medication History:

  5. Subjects who use any drug inhibiting or inducing hepatic drug-metabolizing enzyme activity (see Appendix 1 for details) within 30 days before screening;
  6. Subjects who use any prescription drugs, over-the-counter drugs, Chinese herbal medicines and food supplements (such as vitamins and calcium supplements) from 14 days before screening to predose;

    Disease and Surgical History:

  7. Subjects who have febrile illness or active infection within 14 days before screening;
  8. Subjects who have gastrointestinal diseases causing clinically significant symptoms such as nausea, vomiting, diarrhea or malabsorption syndrome, or a history of severe vomiting or diarrhea within one week before screening;
  9. Subjects who have a history of any clinically significant disease or any disease or condition that may affect the study results in the opinion of the investigator, including but not limited to cardiovascular system, respiratory system, endocrine system, nervous system, digestive system, urinary system or blood, immune, mental and metabolic diseases;
  10. Subjects who have dysphagia or any condition that may affect oral administration and drug absorption (e.g., cholecystectomy, gastric bypass, duodenotomy, colectomy, post-gastrointestinal resection, ulcerative colitis, symptomatic/inflammatory bowel disease, intestinal obstruction, etc.);
  11. Subjects who have undergone major surgery within 6 months before screening or have incomplete healing of surgical incision, including but not limited to any surgery with significant bleeding risk, prolonged general anesthesia, or incisional or significant traumatic injury; or who have undergone surgery affecting drug absorption, distribution, metabolism, excretion, or plan to undergo surgery during the study period;
  12. Subjects who have drug, environmental, food allergy or allergic constitution, or may be allergic to the product judged by the investigator;
  13. Subjects who have hemorrhoids or perianal diseases accompanied by regular/ongoing hematochezia, irritable bowel syndrome, inflammatory bowel disease;

    Life Style:

  14. Habitual constipation or diarrhea;
  15. Subjects who have alcoholism or regular drink within 6 months before screening, defined as drinking more than 14 units of alcohol per week (1 unit = 360 mL of beer or 45 mL of spirits 40% or 150 mL of wine), or have a breathalyzer test result > 0 mg/100 ml at screening, or unable to abstain from alcohol during the study;
  16. Subjects who smoke more than 5 cigarettes per day or habitually use nicotine-containing products within 3 months before screening, or inability to abstain during the study;
  17. Subjects who abuse drugs or use soft drugs (such as marijuana) 3 months before screening or take hard drugs (such as amphetamines, phencyclidine, etc.) 1 year before screening; or have positive urine drug test during screening;
  18. Subjects who have special requirements for diet or fail to follow the standard diet (such as intolerant of standard meals); habitually drink grapefruit juice or excessive tea, coffee and/or caffeine beverages, or unable to abstain during the study; refuse to discontinue any beverages containing xanthine derivatives, such as caffeine (coffee, tea, cola, chocolate, etc.) from 48 hours pre-dose until the end of the study; refuse to discontinue animals' viscera, seafood, soy products and other foods containing high purine;
  19. Subjects who have strenuous exercise or other factors affecting drug absorption, distribution, metabolism and excretion;
  20. Lactose intolerance (subjects who have had diarrhea from drinking milk);

    Others:

  21. Subjects who are exposed to radioactivity for a prolonged period, or have significant radiation exposure (≥ 2 chest/abdominal CT scans, or ≥ 3 other X-ray examinations) within one year before screening, or have participated in radiopharmaceutical labeling trials within one year before screening;
  22. Subjects who have a history of syncope due to the needles or blood, or difficult blood collection or cannot tolerate venipuncture for blood collection;
  23. Subjects who have participated in any clinical trial within 3 months before screening and have received an investigational product or used an investigational device; or those who plan to participate in other clinical trials during this study, or subjects who do not participate in the clinical trial in person;
  24. Subjects who have been vaccinated within 1 month before screening or planned to receive vaccination during the study;
  25. Subjects who plan to father a child or donate sperm from the time of signing the form to 1 year after completing the study, or do not agree to take strict measures (see Appendix 3 for details) for themselves and their spouses from the time of signing the informed consent form to 1 year after completing the study;
  26. Subjects who have blood loss or blood donation ≥ 400 mL within 3 months before screening, or blood transfusion or blood component within 1 month before screening, or blood donor during planned medication and within 3 months after discontinuation;
  27. Subjects who have any other factor that the investigator considers inappropriate for participation in this study or the subject withdraws from the study for his/her own reasons.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
6 participants (actual)

Study arms

  • Experimental
    [14C]TJ0113

    A single oral dose of approximately 200 mg/100 μCi of the oral formulation of \[14C\] TJ0113

    Drug: [14C]TJ0113

Interventions

  • Subjects will receive a single oral dose of approximately 200 mg/100 μCi of the oral formulation of \[14C\] TJ0113 under fasted conditions.

06

What researchers measure

Primary outcomes

  1. The excretion ratio of total radioactivity at each time interval and the cumulative recovery of total radioactivity in urine and feces

    The excretion ratio of total radioactivity at each time interval and the cumulative recovery of total radioactivity in urine and feces

    Time frame: Predose up to 240 hours after administration of [14C]TJ0113

  2. Pharmacokinetic parameters of total radioactivity in plasma: Cmax

    Maximum concentration

    Time frame: Predose up to 168 hours after administration of [14C]TJ0113

  3. Pharmacokinetic parameters of total radioactivity in plasma: Tmax

    Time to Maximum Concentration

    Time frame: Predose up to 168 hours after administration of [14C]TJ0113

  4. Pharmacokinetic parameters of total radioactivity in plasma: t1/2

    Half Life

    Time frame: Predose up to 168 hours after administration of [14C]TJ0113

  5. Pharmacokinetic parameters of total radioactivity in plasma: MRT

    Mean Residence Time

    Time frame: Predose up to 168 hours after administration of [14C]TJ0113

  6. Pharmacokinetic parameters of total radioactivity in plasma: AUC

    Area Under the Plasma Concentration-time Curve

    Time frame: Predose up to 168 hours after administration of [14C]TJ0113

07

Study locations

1 site
  • Affiliated Hospital of Jiangnan University
    Wuxi, Jiangsu, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2025 to primary completion in Mar 2025, 0 months.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 6, 2025
First posted
Feb 18, 2025
StartActual
Feb 19, 2025
Primary completionActual
Mar 5, 2025
CompletionActual
Mar 5, 2025
Last update
Nov 17, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 17, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06832540
Lead sponsor
Hangzhou PhecdaMed Co., Ltd.
Responsible party
Sponsor
First posted
Feb 18, 2025
Start date
Feb 19, 2025
Primary completion
Mar 5, 2025
Completion
Mar 5, 2025
Last update
Nov 17, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: TJ0113

Start the discussion